Target intelligence / Profile preview

Gamma-aminobutyric acid interneuron

Molecular classification
Other (cell type; not an individual molecule or receptor)
01

Overview

GABAergic interneurons are a broad and diverse class of inhibitory neurons defined by their ability to synthesize and release gamma-aminobutyric acid (GABA). They regulate neural circuit excitability, synchronize activity across neural networks, and shape behavioral and cognitive patterns[2][3][5][7]. These interneurons are highly heterogeneous, classified by molecular markers (such as parvalbumin, somatostatin, calretinin, neuropeptide Y, and others), anatomical features, and physiological properties[6][4]. They play essential roles in central nervous system function and development, and their dysfunction is implicated in various neurodevelopmental and neuropsychiatric disorders. However, \"GABAergic interneuron\" is not a single molecule or a canonical therapeutic target category such as a receptor, enzyme, or transporter[5][7].\n\nThis entry should not be treated as a canonical molecule/receptor target for drug development purposes, but rather as a heterogeneous cell class that expresses multiple potential molecular therapeutic targets (such as GABA-A receptors, various ion channels, and synaptic proteins).

Other names
GABA interneuroninhibitory interneuronGABAergic neurongamma-aminobutyric acid interneuron
02

Mechanism of action

Potentiation of GABA-A receptor-mediated inhibition (e.g., enhancement of chloride currents by benzodiazepines or barbiturates at the postsynaptic GABA-A receptors of postsynaptic neurons); interneuron activity modulation can also be influenced by drugs acting on their synapses

03

Biological functions

Inhibition of neuronal activitynetwork oscillation regulationneural circuit modulationcontrol of action potential firingshaping of principal cell behavior
04

Disease associations

Neurodevelopmental disorders (including epilepsy)schizophreniaautism spectrum disordersneurodegenerative diseases
05

Safety considerations

Non-selectivity—therapeutic targeting of all GABAergic interneurons can impair normal brain inhibition, leading to cognitive side effects, sedation, or seizuressubtype-selectivity is a key challenge
06

Interacting drugs

Benzodiazepines

2 more in the full profile.

07

Biomarkers

GAD65 and GAD67 (glutamate decarboxylase isoforms)parvalbumin (PV)somatostatin (SOM)calretinin (CR)neuropeptide Y (NPY)vasoactive intestinal peptide (VIP)cholecystokinin (CCK)5HT3aR (serotonin receptor)

Beyond the preview

Go deeper on Gamma-aminobutyric acid interneuron.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gamma-aminobutyric acid interneuron.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call